HC Wainwright Predicts Urogen Pharma Q3 Earnings

Key Points

• HC Wainwright analyst R. Selvaraju projects UroGen will earn $0.27 EPS in Q3 2027, while the consensus full‑year estimate remains negative at ($1.20) per share.
• URGN shares opened at $24.31 and were down 6.7%, trading within a 12‑month range of $3.42–$30.00 with a market cap of $1.18B; analysts' consensus is a Moderate Buy with an average price target of $34.13.
• Company insiders recently sold shares (Mark Schoenberg ~7,373 and General Counsel Jason Drew Smith ~7,479 at $19.69 each), insiders own 4.70% of stock while institutional investors hold about 91.29%.

Urogen Pharma (NASDAQ:URGN - Free Report) - HC Wainwright issued their Q3 2027 earnings per share estimates for shares of Urogen Pharma in a report released on Thursday, April 23rd. HC Wainwright analyst R. Selvaraju forecasts that the company will earn $0.27 per share for the quarter. The consensus estimate for Urogen Pharma's current full-year earnings is ($1.20) per share.

URGN has been the subject of a number of other reports. Oppenheimer restated an "outperform" rating on shares of Urogen Pharma in a research note on Monday, March 2nd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Urogen Pharma in a report on Monday. Jefferies Financial Group began coverage on shares of Urogen Pharma in a research report on Friday, April 10th. They set a "buy" rating and a $40.00 target price for the company. Finally, D. Boral Capital reaffirmed a "buy" rating and issued a $33.00 price target on shares of Urogen Pharma in a research report on Tuesday, March 31st. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $34.13.

Urogen Pharma Stock Down 6.7%

Shares of URGN stock opened at $24.31 on Friday. Urogen Pharma has a 12 month low of $3.42 and a 12 month high of $30.00. The company has a market cap of $1.18 billion, a PE ratio of -7.60 and a beta of 1.43. The business's 50 day moving average is $20.03 and its two-hundred day moving average is $21.08.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($0.54) earnings per share for the quarter, beating analysts' consensus estimates of ($0.66) by $0.12. The company had revenue of $37.84 million during the quarter, compared to the consensus estimate of $39.92 million.

Insider Activity at Urogen Pharma

In related news, insider Mark Schoenberg sold 7,373 shares of the firm's stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total value of $145,174.37. Following the completion of the transaction, the insider directly owned 144,985 shares of the company's stock, valued at $2,854,754.65. This trade represents a 4.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Jason Drew Smith sold 7,479 shares of Urogen Pharma stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total transaction of $147,261.51. Following the sale, the general counsel owned 51,326 shares in the company, valued at $1,010,608.94. This represents a 12.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 4.70% of the stock is currently owned by company insiders.

Institutional Trading of Urogen Pharma

Institutional investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. increased its stake in Urogen Pharma by 27.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company's stock valued at $53,000 after acquiring an additional 486 shares during the period. CWM LLC boosted its holdings in Urogen Pharma by 18.0% during the third quarter. CWM LLC now owns 4,271 shares of the company's stock valued at $85,000 after purchasing an additional 650 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Urogen Pharma by 7.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company's stock valued at $258,000 after purchasing an additional 1,653 shares during the period. Main Street Financial Solutions LLC raised its holdings in shares of Urogen Pharma by 8.2% in the 2nd quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company's stock worth $356,000 after buying an additional 1,968 shares in the last quarter. Finally, Barclays PLC raised its holdings in shares of Urogen Pharma by 3.8% in the 4th quarter. Barclays PLC now owns 57,744 shares of the company's stock worth $1,352,000 after buying an additional 2,125 shares in the last quarter. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra'anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company's lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.